Press Releases

GlobeNewswire, Inc.

Second quarter worldwide net sales totaled $210 million Gross margin expanded 490 basis points to 62.4% Second quarter operating income of $3 million and operating margin of 2%; constant currency adjusted operating income of $9 million and...

GlobeNewswire, Inc.

Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients including those with a broad range...

GlobeNewswire, Inc.

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock...

GlobeNewswire, Inc.

Improved Fleet Efficiency and Aircraft Utilization Drive EBITDA Growth Despite Fewer Net Available Aircraft Advances Fleet Modernization Initiative with Five New A320 Aircraft — On Track to Reach 25-Aircraft Target by Year-End MIAMI, Aug. 12, 2026...

GlobeNewswire, Inc.

Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with...

GlobeNewswire, Inc.

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication...

GlobeNewswire, Inc.

SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the...

GlobeNewswire, Inc.

Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM), a...

GlobeNewswire, Inc.

Management to Host Conference Call Today at 5:00 p.m. Eastern Time AUSTIN, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Forward Industries, Inc. (NASDAQ: FWDI) (the “Company” or “Forward”), the leading Solana treasury company, today announced its...

GlobeNewswire, Inc.

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive...

GlobeNewswire, Inc.

Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA(8) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets Since June 2026 Sale of Remaining...

GlobeNewswire, Inc.

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy Strong Execution and Increased...

GlobeNewswire, Inc.

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least...

GlobeNewswire, Inc.

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on...

GlobeNewswire, Inc.

ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion...

GlobeNewswire, Inc.

GONZALES, La., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) a producer, designer, and distributor of infant, toddler, and juvenile consumer products, today reported results for the first quarter fiscal...

GlobeNewswire, Inc.

– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class,...

GlobeNewswire, Inc.

– Q2 revenue totals $20.5 million – Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively – Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million – Completed...

GlobeNewswire, Inc.

Revenue, Earnings per Share, and Adjusted EBITDA1 beat Consensus Estimates Revenue up 19%, Adjusted EBITDA1 up 128% Raises Fiscal 2026 Revenue Guidance, Revenues Now Expected to be up 14-16% Total payment dollars processed through all payment...

GlobeNewswire, Inc.

The Company Names Andy D’Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027 Planned Transition Reflects Strong Succession Planning and Deep Leadership Bench WALTHAM, Mass., Aug. 12,...